



ps://linkinghub.elsevier.com/retrieve/pii/S0140673609614549

**24.** Dillinger J-G, Gregory DUCROCCQ, Elbez Y, et al. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. *Circulation: Cardiovascular Interventions* [online]. 2018, 11(6) [cit. 2019-03-26]. DOI: 10.1161/CIRCINTERVENTIONS.118.006084. ISSN 1941-7640. Dostupné z: <https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.118.006084>

**25.** Deharo P, Ducrocq G, Bode CH, et al. Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively. *Circulation* [online]. 2017, 136(20), 1895-1907 [cit. 2019-03-26]. DOI: 10.1161/CIRCULATIONAHA.117.029779. ISSN 0009-7322. Dostupné z: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029779>

**26.** Steg PG. Anticoagulation With Otamixaban and Ischemic Events in Non-ST-Segment Elevation Acute Coronary Syndromes. *JAMA* [online]. 2013, 310(11) [cit. 2019-03-26]. DOI: 10.1001/jama.2013.277165. ISSN 0098-7484. Dostupné z: <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.277165>

**27.** Dhakal P, Rayamajhi S, Verma V, Gundabolu K, Bhatt VR. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. *Clinical and Applied Thrombosis/Hemostasis* [online]. 2016, 23(5), 410-415 [cit. 2019-03-27]. DOI: 10.1177/1076029616675970. ISSN 1076-0296. Dostupné z: <http://journals.sagepub.com/doi/10.1177/1076029616675970>

**28.** Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anti-coagulants. *Nature Reviews Cardiology* [online]. 2018, 15(5), 273-281 [cit. 2019-03-27]. DOI: 10.1038/nrcardio.2017.223. ISSN 1759-5002. Dostupné z: <http://www.nature.com/doi/10.1038/nrcardio.2017.223>

**29.** Crowther M, Cuker A. How can we reverse bleeding in patients on direct oral anti-coagulants? *Kardiologia Polska* [online]. 2019, 77(1), 3-11 [cit. 2019-03-27]. DOI: 10.5603/KP.a2018.0197. ISSN 1897-4279. Dostupné z: <https://ojs.kardiologiapolska.pl/kp/article/view/12634>

**30.** Ansell JE, Bakhru SH, Laulicht BE, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. *Thrombosis and Haemostasis* [online]. 2017, 117(02), 238-245 [cit. 2019-03-27]. DOI: 10.1160/TH16-03-0224. ISSN 0340-6245. Dostupné z: <http://www.thieme-connect.de/DOI/DOI?10.1160/TH16-03-0224>

**31.** Dabi A, Koutrouvelis AP. Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications. *Critical Care Research and Practice* [online]. 2018, 2018, 1-11 [cit. 2019-03-27]. DOI: 10.1155/2018/4907164. ISSN 2090-1305. Dostupné z: <https://www.hindawi.com/journals/ccrp/2018/4907164/>

**32.** Riley TR, Gauthier-Lewis ML, Sanchez CHK, DOUGLAS JS. Role of agents for reversing the effects of target-specific oral anticoagulants. *American Journal of Health-System Pharmacy* [online]. 2017, 74(2), 54-61 [cit. 2019-03-27]. DOI: 10.2146/ajhp150810. ISSN 1079-2082. Dostupné z: <https://academic.oup.com/ajhp/article/74/2/54/5102888>